|
KMID : 0614720090520100963
|
|
Journal of Korean Medical Association
2009 Volume.52 No. 10 p.963 ~ p.974
|
|
|
Drug Therapy for Breast Cancer
|
|
Park Yeon-Hee
|
|
|
Abstract
|
|
|
|
Breast cancer is the second common cancer and the leading cause of cancer deaths in women in Korea. Contrary to public perception, it is a heterogeneous disease with varying morphology, prognosis, and response to therapy. Understanding of the tumor biology results in marked advance in drug therapy proceeding to individualized molecular targeted therapy using predictive biomarkers (hormonal receptor: HR and human epidermal growth factor receptor -2: HER2). This review considers various drug therapeutic options based on biologic background of breast cancer divided into metastatic, neoadjuvant, and adjuvant systemic drug therapies. These are conventional cytotoxic chemotherapy, hormonal therapy, and molecular targeted therapies including trastuzumab, an anti-HER2 monoclonal antibody. In addition, bisphosphonate to improve outcomes of bone metastasis has seen an increased usage in adjuvant and metastatic setting. Microarray based genomic, transcription, and proteomic methods are transforming classification systems and identifying novel targets for the development of new therapeutics. It is important for us to appreciate and embrace the new developments as they will impact on daily clinical practice and require understanding of biomarkers as a tool for the determination of treatment options.
|
|
|
KEYWORD
|
|
|
Breast cancer, Chemotherapy, Hormone receptor, HER2, Molecular targeted therapy
|
|
|
FullTexts / Linksout information
|
|
 
|
|
|
Listed journal information
|
|
 
|
|